Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Biol Sci 2012; 8(1):1-14. doi:10.7150/ijbs.8.1 This issue Cite

Research Paper

Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway

Wei-Tian Wei2,3,#, Hui Chen3, #, Zhao-Hong Wang3, Zhong-Lin Ni3, Hai-Bin Liu3, Hong-Fei Tong3, Hong-Chun Guo3, Dian-Lei Liu3, Sheng-Zhang Lin1,3,✉

1. Department of Hepato-biliary-pancreatic Surgery, First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
2. Department of Oncological Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
3. Department of Hepato-biliary-pancreatic Surgery, Second Affiliated Hospital of Wenzhou Medical College, Zhejiang, China.
# These authors contributed equally to this work.

✉ Corresponding author: Sheng-Zhang Lin, Tel: 86-577-88879016; Fax: 86-577-88816191; Email: zysxswzszedu.cn.

Citation:
Wei WT, Chen H, Wang ZH, Ni ZL, Liu HB, Tong HF, Guo HC, Liu DL, Lin SZ. Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway. Int J Biol Sci 2012; 8(1):1-14. doi:10.7150/ijbs.8.1. https://www.ijbs.com/v08p0001.htm
Other styles

File import instruction

Abstract

Evodiamine has therapeutic potential against cancers. This study was designed to investigate whether combination therapy with gemcitabine and evodiamine enhanced antitumor efficacy in pancreatic cancer. In vitro application of the combination therapy triggered significantly higher frequency of pancreatic cancer cells apoptosis, inhibited the activities of PI3K, Akt, PKA, mTOR and PTEN, and decreased the activation of NF-κB and expression of NF-κB-regulated products. In vivo application of the combination therapy induced significant enhancement of tumor cell apoptosis, reductions in tumor volume, and inhibited activation of mTOR and PTEN. In conclusion, evodiamine can augment the therapeutic effect of gemcitabine in pancreatic cancer through direct or indirect negative regulation of the PI3K/Akt pathway.

Keywords: evodiamine, gemcitabine, pancreatic cancer SW1990 cells, apoptosis, PTEN, mTOR

Citation styles

APA
Wei, W.T., Chen, H., Wang, Z.H., Ni, Z.L., Liu, H.B., Tong, H.F., Guo, H.C., Liu, D.L., Lin, S.Z. (2012). Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway. International Journal of Biological Sciences, 8(1), 1-14. https://doi.org/10.7150/ijbs.8.1.

ACS
Wei, W.T.; Chen, H.; Wang, Z.H.; Ni, Z.L.; Liu, H.B.; Tong, H.F.; Guo, H.C.; Liu, D.L.; Lin, S.Z. Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway. Int. J. Biol. Sci. 2012, 8 (1), 1-14. DOI: 10.7150/ijbs.8.1.

NLM
Wei WT, Chen H, Wang ZH, Ni ZL, Liu HB, Tong HF, Guo HC, Liu DL, Lin SZ. Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway. Int J Biol Sci 2012; 8(1):1-14. doi:10.7150/ijbs.8.1. https://www.ijbs.com/v08p0001.htm

CSE
Wei WT, Chen H, Wang ZH, Ni ZL, Liu HB, Tong HF, Guo HC, Liu DL, Lin SZ. 2012. Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway. Int J Biol Sci. 8(1):1-14.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use